Europe
The new company celebrated the grand opening of its 100-employee Boston facility that will initially focus its efforts on developing oncology therapies.
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Merck is planning a $1 billion expansion to its manufacturing facility in Elkton, Va. over the course of the next three years that will include the addition of approximately 100 new jobs, the office of the governor of Virginia announced Wednesday.
Merck and Co. announced that its investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age.
The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda’s strategy to pare down debt from its $62 billion acquisition of Shire.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
With key investors upset about Allergan’s share price, Saunders pointed to five potential drugs on the market within the next 18 months.
PRESS RELEASES